KLK10 Upregulation Drives Aggressiveness and Radioresistance and Has a Negative Prognostic Impact on Rectal Cancer.

PURPOSE: Rectal cancer is a heterogeneous disease with widely variable treatment responses. Beyond the TNM staging system, no reliable biomarkers currently exist to predict the efficacy of concurrent chemoradiotherapy (CCRT) in rectal cancer, limiting the personalization of curative-intent treatment. Proteolytic enzymes promote extracellular matrix degradation and tumor progression, with serine proteases playing a key role. Consequently, this study intended to investigate their potential to predict preoperative CCRT response and survival in rectal cancer.

MATERIALS AND

METHODS

Associations between protein immunostaining and clinicopathological features were analyzed using Pearson's chi-square test. Survival was evaluated by the Kaplan-Meier method with the log-rank test, while independent prognostic factors were identified using Cox proportional hazards regression analysis.

RESULTS

In our rectal cancer cohort (n = 343), high kallikrein-related peptidase 10 (KLK10) immunoreactivity was considerably linked to adverse clinicopathological characteristics, comprising pre-CCRT nodal status (cN1-N2; P = 0032), post-CCRT tumor stage (ypT3-T4; P = .001), post-CCRT nodal status (ypN1-N2; P < .001), perineural invasion (P < .001), vascular invasion (P < .001), and poor tumor regression (P = .001). Multivariate survival analyses indicated that high KLK10 immunoreactivity was independently correlated with worse disease-specific survival (hazard ratio [HR], 3.647; 95% CI, 1.854-7.171; P < .001), locoregional recurrence-free survival (HR, 3.591; 95% CI, 1.523-8.463; P = .003), and metastasis-free survival (HR, 2.459; 95% CI, 1.346-4.492; P = .003). Additionally, cellular analyses revealed that KLK10 contributes to cancer progression by promoting aggressive phenotypes and radiation resistance.

CONCLUSIONS

These findings suggest that KLK10 could be a predictive and prognostic biomarker as well as a promising therapeutic target in rectal cancer.